Buy Or Sell Opportunity • Jun 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to CN¥4.67. The fair value is estimated to be CN¥5.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 0.1% in a year. Earnings are forecast to grow by 14% in the next year. Tillkännagivande • May 30
COFCO Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2025 COFCO Biotechnology Co., Ltd. held its Annual General Meeting of 2025 on 27 May 2026, during which the following proposal(s) was/were approved: Cash dividend/10 shares (tax included) of CNY 0.30000000 for the year 2025. Board Change • May 20
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Employee Supervisor Zhi Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Apr 24
COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026 COFCO Biotechnology Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China Tillkännagivande • Mar 31
COFCO Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026 COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Tillkännagivande • Dec 31
COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Tillkännagivande • Sep 30
COFCO Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025 COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Tillkännagivande • Jul 02
COFCO Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 COFCO Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Tillkännagivande • Apr 26
COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025 COFCO Biotechnology Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaotai International Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China Tillkännagivande • Apr 02
COFCO Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Tillkännagivande • Dec 31
COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: CN¥0.028 loss per share (vs CN¥0.001 profit in 3Q 2023) Third quarter 2024 results: CN¥0.028 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥5.21b (down 3.7% from 3Q 2023). Net loss: CN¥51.9m (down CN¥54.3m from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Tillkännagivande • Sep 30
COFCO Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Tillkännagivande • Sep 21
COFCO Biotechnology Co., Ltd. Announces Board Changes COFCO Biotechnology Co., Ltd. at its EGM held on 19 September 2024 appointed Zhang Deguo, Zheng Heshan as non-independent director; appointed Zhang Nianchun and Wang Ping as independent director. Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.18 loss in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.02 (up from CN¥0.18 loss in 2Q 2023). Revenue: CN¥5.18b (up 8.2% from 2Q 2023). Net income: CN¥36.6m (up CN¥373.3m from 2Q 2023). Profit margin: 0.7% (up from net loss in 2Q 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jun 29
COFCO Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 COFCO Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Board Change • Jun 12
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. GM & Non-Independent Director De Guo Zhang is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.001 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.013 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥4.73b (up 4.6% from 1Q 2023). Net income: CN¥24.8m (up CN¥23.4m from 1Q 2023). Profit margin: 0.5% (up from 0% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Tillkännagivande • Apr 26
COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024 COFCO Biotechnology Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 22F, Tower A, Zhaitai Int'l Center, Chaoyangmen South Avenue, Chaoyang District, Beijing China Tillkännagivande • Mar 30
COFCO Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 COFCO Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Tillkännagivande • Dec 29
COFCO Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 COFCO Biotechnology Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 New Risk • Nov 23
New major risk - Revenue and earnings growth Earnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 0.2% per year over the past 5 years. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.097 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.097 in 3Q 2022). Revenue: CN¥5.41b (up 26% from 3Q 2022). Net income: CN¥2.38m (down 99% from 3Q 2022). Profit margin: 0% (down from 4.2% in 3Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Tillkännagivande • Sep 30
COFCO Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 COFCO Biotechnology Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Buying Opportunity • Sep 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Aug 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥8.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 26
Second quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.23 profit in 2Q 2022) Second quarter 2023 results: CN¥0.18 loss per share (down from CN¥0.23 profit in 2Q 2022). Revenue: CN¥4.79b (down 8.4% from 2Q 2022). Net loss: CN¥336.7m (down 177% from profit in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jun 28
COFCO Biotechnology Co., Ltd. Implements Cash Dividend (A shares) for 2022, Payable on July 03, 2023 COFCO Biotechnology Co., Ltd. announced implementation of cash dividend (tax included) (A shares) of CNY 5.70000000 per 10 shares. Record date: 30 June 2023. Ex-date: 03 July 2023. Payment date: 03 July 2023. Reported Earnings • Apr 16
Full year 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.61 in FY 2021) Full year 2022 results: EPS: CN¥0.57 (down from CN¥0.61 in FY 2021). Revenue: CN¥19.9b (down 15% from FY 2021). Net income: CN¥1.06b (down 6.6% from FY 2021). Profit margin: 5.3% (up from 4.8% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.097 (vs CN¥0.13 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.097 (down from CN¥0.13 in 3Q 2021). Revenue: CN¥4.29b (down 29% from 3Q 2021). Net income: CN¥179.7m (down 24% from 3Q 2021). Profit margin: 4.2% (up from 3.9% in 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 25
Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.23 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥5.23b (down 18% from 2Q 2021). Net income: CN¥436.7m (up 25% from 2Q 2021). Profit margin: 8.4% (up from 5.5% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 8.2%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 30
First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.19 in 1Q 2021). Revenue: CN¥5.38b (down 4.3% from 1Q 2021). Net income: CN¥349.0m (down 1.9% from 1Q 2021). Profit margin: 6.5% (up from 6.3% in 1Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 43% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.091 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥6.06b (up 30% from 3Q 2020). Net income: CN¥234.9m (up 40% from 3Q 2020). Profit margin: 3.9% (up from 3.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Board Change • Sep 12
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Sep 09
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Shihui Li is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 28
Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.14 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥6.38b (up 22% from 2Q 2020). Net income: CN¥350.2m (up 32% from 2Q 2020). Profit margin: 5.5% (up from 5.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 15
Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.32 in FY 2019) The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥19.9b (up 2.2% from FY 2019). Net income: CN¥593.1m (flat on FY 2019). Profit margin: 3.0% (in line with FY 2019). Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥9.07, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 27.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total returns to shareholders over the past year are 11%. Is New 90 Day High Low • Jan 25
New 90-day high: CN¥10.11 The company is up 19% from its price of CN¥8.47 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 25% over the same period. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥9.64, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20.8x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past year are 43%. Is New 90 Day High Low • Jan 05
New 90-day high: CN¥9.64 The company is up 15% from its price of CN¥8.39 on 30 September 2020. The Chinese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 16% over the same period. Reported Earnings • Oct 26
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥737.4m, up 120% from the prior year. Total revenue was CN¥19.6b over the last 12 months, up 6.2% from the prior year.